applied a series of filters to CGP results from >125,000 tissue and liquid biopsies, identifying potentially pathogenic germline variants in 9.7% of biopsies, including 6.8% of liquid biopsies, across cancer types and in both expected (e.g., BRCA1/2 in breast cancer) and unexpected (e.g., mutY DNA glycosylase [MUTYH] outside of colorectal cancer) gene/cancer-type contexts [86]. This evidence concerns the gene BRCA1 and cancer.